Wedbush Reiterates “Outperform” Rating for Vor Biopharma (NYSE:VOR)

Vor Biopharma (NYSE:VOR)‘s stock had its “outperform” rating reiterated by Wedbush in a research report issued on Tuesday, Benzinga reports. They currently have a $11.00 target price on the stock. Wedbush’s price target would suggest a potential upside of 488.24% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. HC Wainwright restated a “buy” rating and issued a $17.50 target price on shares of Vor Biopharma in a research report on Thursday, March 21st. Oppenheimer restated an “outperform” rating and issued a $15.00 price objective (down from $17.00) on shares of Vor Biopharma in a report on Thursday, March 21st. Stifel Nicolaus reduced their target price on shares of Vor Biopharma from $15.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, March 21st. Finally, JMP Securities reiterated a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research note on Friday, March 22nd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $13.50.

Vor Biopharma Price Performance

NYSE VOR traded up $0.05 on Tuesday, hitting $1.87. 132,075 shares of the stock were exchanged, compared to its average volume of 292,526. The company’s 50-day moving average price is $2.04 and its two-hundred day moving average price is $2.11. Vor Biopharma has a 52-week low of $1.62 and a 52-week high of $5.70. The company has a market capitalization of $127.57 million, a price-to-earnings ratio of -1.07 and a beta of -0.36.

Vor Biopharma (NYSE:VOR) last announced its quarterly earnings data on Wednesday, March 20th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.10. Equities analysts predict that Vor Biopharma will post -1.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Vor Biopharma stock. Exchange Traded Concepts LLC grew its position in shares of Vor Biopharma Inc. (NYSE:VOR) by 34.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 60,170 shares of the company’s stock after acquiring an additional 15,258 shares during the period. Exchange Traded Concepts LLC owned about 0.09% of Vor Biopharma worth $135,000 at the end of the most recent quarter. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.